Skip to main content
Premium Trial:

Request an Annual Quote

Rob Friel, Mary Beth Thomas, Thomas Scanlan

Rob Friel will become PerkinElmer’s new CEO on Feb. 1, the company announced this week.
Friel, who joined the company as chief financial officer in 1999, became vice chairman and president of the firm’s Life and Analytical Sciences business in 2006. Last year, he was promoted to president and chief operating officer. He also will retain the title of president after assuming the role of CEO.

The North Carolina Biotechnology Center announced this week that Mary Beth Thomas has accepted the newly created position of senior director of Centers of Innovation operations.
Prior to joining COI, Thomas served as statewide director of technology commercialization with the Small Business and Technology Development Center in Raleigh, NC.
Before working at the SBTDC, Thomas was assistant director of the neurosensory program at Tranzyme Pharma in Research Triangle Park, NC. She was also assistant director of the neuroprotection program at Cogent Neuroscience in Durham. 

Znomics has appointed Thomas Scanlan to its scientific advisory board, the company announced this week.
Scanlan is currently the director of the chemical biology program at Oregon
Health and Science University, where he is also a professor of physiology and pharmacology. He was previously a faculty member of the University of California, San Francisco.

Scanlan received the American Chemical Society’s Arthur C. Cope Scholar Award in July.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.